Celyad Oncology S.A.
CYAD
Rang in aandelen
#31829
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aandeelprijs
$0.23358713
Marktkapitalisatie
$11.04M
Verandering (1 dag)
-7.56%
Verandering (1 jaar)
-50.30%
Land
BE
Handel Celyad Oncology S.A. (CYAD)
Categorie
Healthcare
Koersgeschiedenis voor Celyad Oncology S.A. (CYAD)
Hoogste slotkoers: $0.59 op 2023-05-01
Laagste slotkoers: $53.79 op 2015-06-01
Laagste slotkoers: $53.79 op 2015-06-01
Koersgeschiedenis van Celyad Oncology S.A. van 2015 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2023 | -32.17% |
| 2022 | -78.99% |
| 2021 | -49.41% |
| 2020 | -23.42% |
| 2019 | -46.78% |
| 2018 | -48.41% |
| 2017 | 110.39% |
| 2016 | -62.32% |
| 2015 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
